Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.62% is 76% above its 5-year average of 45.24%, around the middle of its 5-year range (-74.44%–208.48%).
5.28% below its 12-month average of 84.06%.
Reported quarterly gross margin; no daily interpolation. Q1 FY2026 (2026-03-31): 72.49%.
GROSS MARGIN
79.62%
GROSS MARGIN AVG TTM
84.06%
GROSS MARGIN AVG 3Y
63.47%
GROSS MARGIN AVG 5Y
45.24%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.28%
CURRENT VS 3Y AVG
+25.45%
CURRENT VS 5Y AVG
+75.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
+85.51%
vs the sector median at left
Market Cap
$47.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
65.99%
Market Cap
$50.95M
Gross Margin
-262.66%
TTM Avg
-246.22%
3Y Avg
-188.06%
5Y Avg
-150.05%
Market Cap
$45.37M
Gross Margin
56.09%
TTM Avg
52.85%
3Y Avg
42.50%
5Y Avg
40.42%
Market Cap
$51.06M
Gross Margin
N/A
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$45.19M
Gross Margin
0.00%
TTM Avg
1.89%
3Y Avg
44.91%
5Y Avg
29.94%
Market Cap
$45.18M
Gross Margin
93.13%
TTM Avg
94.29%
3Y Avg
92.05%
5Y Avg
80.64%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $48.20M | 79.62% | 84.06% | 63.47% | 45.24% |
| Lite Strategy, Inc. (LITS)vs › | $47.47M | 0.00% | 0.00% | 50.00% | 65.99% |
| Clene Inc. (CLNN)vs › | $48.94M | 78.50% | 79.02% | 83.51% | 77.08% |
| biote Corp. (BTMD)vs › | $50.28M | 71.46% | 70.99% | 69.42% | 67.35% |
| Envoy Medical, Inc. (COCH)vs › | $50.95M | -262.66% | -246.22% | -188.06% | -150.05% |
| DarioHealth Corp. (DRIO)vs › | $45.37M | 56.09% | 52.85% | 42.50% | 40.42% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.06M | N/A | 50.00% | 25.00% | 16.67% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.19M | 0.00% | 1.89% | 44.91% | 29.94% |
| BioStem Technologies, Inc. (BSEM)vs › | $45.18M | 93.13% | 94.29% | 92.05% | 80.64% |
| INmune Bio, Inc. (INMB)vs › | $51.31M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
79.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 72.49% |
| 2025-12-31 | 208.48% |
| 2025-09-30 | 61.81% |
| 2025-06-30 | 8.61% |
| 2025-03-31 | 68.90% |
| 2024-12-31 | 59.50% |
| 2024-09-30 | 58.23% |
| 2024-06-30 | 82.47% |
| 2024-03-31 | 88.83% |
| 2023-12-31 | 20.67% |
| 2023-09-30 | 4.86% |
| 2023-06-30 | 72.70% |
| 2023-03-31 | 49.10% |
| 2022-12-31 | -27.08% |
| 2022-09-30 | -74.44% |
| 2022-06-30 | 15.81% |
| 2022-03-31 | 32.17% |
| 2021-12-31 | 4.04% |
| 2021-09-30 | 78.24% |
| 2021-06-30 | 54.96% |
| 2021-03-31 | 53.31% |
| 2020-12-31 | 63.92% |
| 2020-09-30 | 69.21% |
| 2020-06-30 | 57.03% |
| 2020-03-31 | 70.60% |
| 2019-12-31 | 72.55% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
